ORIGINAL PAPER

DHI Increases the Proliferation and Migration of Schwann Cells Through the PI3K/AKT Pathway and the Expression of CXCL12 and GDNF to Promote Facial Nerve Function Repair

De-kun Gao1,2,3 · Lian-hua Sun1,2,3 · Xia-yu Sun1,2,3 · Jun Yang1,2,3 · Jing-chun He1,2,3

Received: 22 March 2021 / Revised: 23 December 2021 / Accepted: 17 January 2022 / Published online: 26 January 2022
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022

Abstract
The facial nerve is one of the vulnerable nerves in otolaryngology. Repair and recovery of facial nerve injury have a high priority in clinical practice. The proliferation and migration of Schwann cells are considered of great significance in the process of nerve injury repair. Danhong injection (DHI), as a common drug for cardiovascular and cerebrovascular diseases, has been fully certified in neuroprotection research, but its role in facial nerve injury is still not clear. Our study found that DHI can promote the proliferation and migration of RSC96 cells, a Schwann cell line, and this effect is related to the activation of the PI3K/AKT pathway. LY294002, an inhibitor of PI3K, inhibits the proliferation and migration of RSC96 cells. Further studies have found that DHI can also promote the expression of CXCL12 and GDNF at gene and protein levels, and CXCL12 is, while GDNF is not, PI3K/AKT pathway-dependent. Animal experiments also confirmed that DHI could promote CXCL12 and GDNF expression and promote facial nerve function recovery and myelin regeneration. In conclusion, our in vitro and in vivo experiments demonstrated that DHI could promote the proliferation and migration of Schwann cells through the PI3K/AKT pathway and increase the expression of CXCL12 and GDNF to promote facial nerve function repair.

Keywords DHI · PI3K/AKT pathway · CXCL12 · GDNF · Facial nerve injury

Introduction
The facial nerve, the seventh cranial nerve in the human body, comes from the brain and crosses the temporal bone, dividing into five branches that control the sensation and movement of the face. The facial nerve is susceptible to tumor, infection, trauma, surgery, and other injuries because

De-kun Gao and Lian-hua Sun have contributed equally to this work.

Jun Yang
yangjun@xinhuamed.com.cn

Jing-chun He
hejingchun@xinhuamed.com.cn

1 Department of Otorhinolaryngology-Head and Neck Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
2 Shanghai Jiaotong University School of Medicine Ear Institute, Shanghai, China
3 Shanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases, Shanghai, China

of its long course [1, 2]. Moreover, the recovery of facial nerve function takes a long time, and the results are not satisfactory. Residual facial paralysis often affects people’s psychological and social activities [3].

Due to the complexity and difficulty of facial nerve repair and substantial clinical demand, peripheral nerve regeneration represented by facial nerve transection injury has become the main focus of research. It was found that peripheral nerve transection injury would first trigger the change of the differentiation state of Schwann cells in the damaged area, which was mainly shown as “repair cells” that support the survival of neurons, guide the regenerative axon to its target, and rewrap the neurons to form myelin [4]. The repair process involving Schwann cells is mainly divided into four parts: (1) Up-regulated expression of neurotrophic factors and proteins that promote axon growth and neuron survival after injury [5, 6]; (2) Recruit a variety of inflammatory factors and immune cells to the damaged area to clear the damaged debris, providing a continuous source of cytokines and promote the vascular formation of distal nerves [7, 8]; (3) Arranged into a special tubular structure to seal myelin, Remak cells
(a reparative Schwann cell) and axons, forming a special repair structure conducive to precise connection [9]; (4) Remove useless cell structures for better nerve repair. Since Schwann cells play an important role in the repair of nerve injury, the mechanism of regeneration, remodeling, or migration of Schwann cells will be helpful for the repair of nerve injury [10].

Danhong injection (DHI) is a modern Chinese medicine made by two kinds of drugs, Salviae Miltiorrhizae (Dan Shen) and Flos Carthami (Hong Hua) with the raw material dose ratio of 3:1 [11]. The main biologically active components of Salviae Miltiorrhizae injection include several kinds of water-soluble bioactive substances (Danshensu, protocatechuic aldehyde, rosemary acid, caffeic acid) and fat-soluble compounds (tanshinone II A and cryptotanshinone). For the adult patient, 4–8 mL DHI has diluted in 20 mL 50% glucose injection, or 20–40 mL DHI was diluted in 250 mL 0.9% normal saline and transfused intravenously [12]. It has many pharmacological activities in vivo, such as anti-oxidation, suppressing platelet adhesion and aggregation, improving microcirculation, improving hemorheology, regulating blood lipids, etc [13]. The main bioactive components of Flos Carthami injection are hydroxyl safflower yellow pigment A (HSYA), and total flavonoids, which have pharmacological effects such as preventing ischemia-reperfusion injury, improving hemodynamics, reducing free radical generation, and increasing nitric oxide generation [14]. Both drugs have the effect of antioxidation and improving blood circulation. They are widely used in clinical practice and numerous clinical observations have confirmed that coronary heart disease, heart failure, stroke, cerebral hemorrhage, vertebrobasilar artery ischemic vertigo, and diabetic peripheral neuropathy receiving DHI therapy got favorable outcomes [15–18].

Given the role of DHI in the central nervous system and diabetic peripheral neuropathy, we hypothesized that DHI could promote the repair of facial nerve function by affecting the proliferation and migration of Schwann cells. In our previous study, we found that CXCL12 significantly enhanced the migration of Schwann cells and the repair of facial nerve function after nerve injury. In addition to this, GDNF is a well-known neurotrophic factor associated with peripheral nerve injury repair. Therefore, in this study, we will investigate the changes in CXCL12 and GDNF expression during the physiological effects of DHI. We first studied the effects of DHI on the proliferation and migration of Schwann cells at the cellular level and explored the underlying mechanisms. Then we studied the biological effects of DHI at the animal level. Finally, our experiments showed that DHI could promote the proliferation and migration of Schwann cells to the injured area through PI3K/Akt pathway, and promote the expression of GDNF to repair neurons.

**Materials and Methods**

**Cell Culture and Reagents**

RSC96 cells were purchased from the Cell Bank of the Chinese Academy of Sciences. They were cultured in a DMEM medium (Hyclone, USA) at 37 °C and 5% CO2, supplemented with 10% fetal bovine serum (Gibco, USA). Cell counting kit 8 (CCK8) was purchased from Beyotime (Shanghai, China). Antibody for PI3K, p-PI3K, AKT, p-AKT1 were purchased from Cell Signaling Technology (Beverly, MA, USA), antibodies for GAPDH, CXCL12, and GNDF was purchased from Beyotime (Shanghai, China), Abcam (Cambridge, MA), and Abclonal (Wuhan, China), respectively. Inhibitor LY294002 was from Selleck Chemicals (Shanghai, China). Danhong Injection was purchased from Buchang Pharmaceutical Company (Shandong, China). RIPA lystate, PMSF, BCA kit, and HRP-labeled secondary antibody were purchased from Beyotime (Shanghai, China). TRIzol reagent was purchased from Takara (Invitrogen, Carlsbad, CA, USA).

**Cell Proliferation Assay**

RSC96 cells were plated in 96-well plates at the density of 1000 cells/well. After the cells adhered to the wall, the cells were cultured with different concentrations of DHI (0.2%, 0.5%, 1%, 2%) for different times (12 and 36 h). Then 10 µL CCK8 solution was added to the well and the absorbance at 490nm was detected by a microplate reader after incubation for 1 h at 37 °C. The OD values obtained from the three measurements were recorded and analyzed.

**Cell Migration Assay**

The effect of DHI on the migration of RSC96 cells was studied by the Transwell chamber (Corning, USA) with a diameter of 8-µm pore size. 250 µL serum-free medium containing 20×10⁶ RSC96 cells was cultured in the upper chamber of Transwell and 500 µL of complete medium containing different concentrations of DHI in the lower chamber. The cells were allowed to migrate for 12 h and then fixed by 4% paraformaldehyde for 15 min, followed by crystal violet staining for 15 min. Cotton swabs were used to erase the non-migrated cells, and then five random fields were photographed and counted under a microscope (Olympus, Japan).
Protein Extraction and Western Blot

The treated cells were washed with PBS three times, then 200 µL RIPA lysate containing protease inhibitors PMSF and cocktail was added and incubated on ice for 15 min, and then the lysate was collected and centrifuged at 12,000 rpm for 15 min. The supernatant was collected and centrifuged for 15 min at 12,000 rpm. The concentration of the supernatant was determined by the BCA kit, and 5X loading buffer was added to the remaining supernatant and boiled at 100 °C for 10 min to denature the protein. A protein of 20 µg was loaded on polyacrylamide gel for electrophoresis and then transferred to PVDF membranes (Thermo Fisher, USA). After blocking with 5% non-fat milk in TBST, the membranes were incubated with anti-PI3K, p-PI3K, anti-AKT, anti-p-AKT, anti-CXCL12, anti-GDNF, and anti-GAPDH at 4 °C overnight, followed by incubating with HRP-conjugated secondary antibody at room temperature for 1 h, washed with TBST, added enhanced chemiluminescent substrates (Millipore, Billerica, MA) and luminescent on Image Lab System (Bio-Rad, USA).

Reverse Transcription-Polymerase Chain Reaction (RT-PCR)

Trizol was added to the cells and tissues washed with pre-cold PBS, which were lysed on ice for 10 min, and then 1/5 volume of chloroform was added. After blending, the mixture was centrifuged at 4 °C for 15 min at 12,000 rpm. The supernatant was added to an equal volume of iso-propanol and centrifuged at 4 °C for 15 min again. Wash the precipitate twice with 75% alcohol and finally dissolve the precipitate with DEPC water. The reverse transcription kit was used to synthesize cDNA. RT-PCR on-machine operation (ABI7500) was performed according to the instructions of the SYBR Green quantitative PCR kit. The primers were as follows:

CXCL12 Forward GTG ACG GTA AGC CAG TCA GC.
CXCL12 Reverse TGC ACA CTT GTC TGT TGT TGC.
GDNF Forward GAA CCA AGC-CAG TGT ATC TCC T.
GDNF Reverse ATC GTC TCT-GCC TTT GTC CTC .
GAPDH Forward CAG TGC CAG CCT CGT CTC AT.
GAPDH Reverse AGG GGC CAT CCA CAG TCT TC.

Reaction conditions were as follows: 5 min at 95 °C, followed by 40 cycles of 30 s. at 95 °C, 30 s. at 57 °C, and 30 s. at 72 °C. The expression level of the target gene was calculated by $2^{-\Delta\Delta CT}$.

Enzyme-Linked Immunosorbent Assay (ELISA)

The ELISA method for the detection of facial nerve tissues in rats was the same as the previous method [19]. In short, the facial nerve tissue was taken out, and then 100 uL RIPA lysate was added to every 50 mg nerve tissue block to fully grind the tissue until the tissue mass disappeared. The test was then performed according to the ELISA procedure. The detection of the supernatant in cell culture was directly based on the instructions.

Experimental Animals and Ethics

The animals used in this experiment were Sprague-Dawley rats, weighing between 180 and 200 g. The animals lived 12 h a day and 12 h a night, with sufficient water and food. All animal procedures were performed according to a protocol approved by the Institutional Animal Care and Use Committee of Shanghai Jiao Tong University School of Medicine. A total of 60 adult male Sprague-Dawley rats were used in this experiment. Rats were randomly divided into five groups (12 rats per group): sham group (Sham), facial nerve injury group (FNI), low dose Danhong injection group (L + DHI), moderate dose Danhong injection group (M + DHI), and high dose Danhong injection group (H + DHI). In the low, moderate, and high dose DHI groups, the injection concentrations were 0.5, 1, and 2 mL/kg, which were 5, 10, and 20 times higher than the dose for human beings of 0.1 mL/kg, respectively.

Facial Nerve Injury Model

The rat model was established based on our published article [19]. Briefly, rats were anesthetized by intraperitoneal injection of 1% Pentobarbital Sodium at a dose of 40 mg/kg. After successful anesthesia, the right posterior auricular incision was made, and the main facial nerve and its three branches were dissected and exposed, and then the facial nerve trunk was clamped with a vascular clamp for 50 s. Immediately after injury, the rats in the experimental group were intravenously administrated with different concentration of DHI for 28 days.

Facial Nerve Function Evaluation

The facial nerve function was evaluated referring to previous methods [20], which contains two aspects: Vibrissae observation, eye closing, and blinking reflex observation. The specific scoring criteria are as follows:

The absence of eye blinking and closure scored 1; the presence of orbicular muscle contraction without blinking reflex scored 2; 50% of eye closure through blinking reflex, scored 3, 75% of closure scored 4. The presence of complete eye closure and blinking reflex scored 5. The absence of movement and posterior position of the vibrissae scored 1; slight shivering and posterior position scored 2; greater shivering and posterior position scored 3 and normal movement with a posterior position scored 4; the symmetrical
movement of the vibrissae, with an anterior position, scored 5. The facial nerve function was evaluated on the 1st day, 7th, 14th, and 28th day after the establishment of the model.

Immunofluorescence Staining

After 28 days of the experiment, the facial nerve tissues were taken, followed by fixing with 4% polymerized paraffin embedding, slicing, dewaxing, antigen repairing, and serum blocking. Then facial nerve tissue sections were incubated with the primary antibody for 4 degrees overnight and incubated with the second antibody for 2 h at room temperature the next day. After PBS cleaning, DAPI was added to stain the nucleus and finally observed under the OLYMPUS fluorescence microscope.

Transmission Electron Microscopy (SEM)

The obtained nerve tissues were placed in 2.5% glutaraldehyde, and then made into sections of approximately 80-100 nm thickness after osmium acid fixation, gradient alcohol dehydration, infiltration, embedding, and sectioning steps, respectively, followed by uranium-lead double staining (2% uranyl acetate saturated aqueous solution, lead citrate), staining at room temperature for 15 min and drying overnight for observation under electron microscopy.

Statistical Analysis

Data were presented as mean ± standard deviation and analyzed by Graphpad Prism 8.0 software. All data were obtained by at least three independent experiments. Statistical analysis was conducted by t-test and one-way analysis of variance (ANOVA); p < 0.05 was considered for statistical significance.

Results

DHI Promotes the Proliferation of RSC96 Cells

The effects of DHI on the proliferation of RSC96 cells were examined using a CCK-8 assay. Since DHI is used every 12 h in the human body, to observe the sustained effect of DHI on RSC96 cells, we selected 12 and 36 h as observation points. It can be seen from Fig. 1 that after 12 h of DHI treatment, the proliferation ability of RSC96 cells was higher than that of the control group, but the effect of 0.2% and 0.5% DHI had no statistical significance, and the effect of DHI functioning for 36 h was similar (Fig. 1A). Therefore, it is likely that 1% and 2% DHI promoted the proliferation of RSC96 cells.

DHI Promotes the Migration of RSC96 Cells

We further used Transwell assay to observe the effect of DHI on the migration of RSC96 cells. We chose 12 h as the endpoint of migration and observed the number of migrated cells that were stained purple with crystal violet. As shown in Fig. 1B, different concentrations of DHI significantly promoted migration in a dose-dependent manner, however, there was no significant difference between 1% and 2% concentrations of DHI. Combined with the effect of DHI on cell proliferation and migration, we chose 1% DHI concentration in subsequent experiments.
PI3K/Akt Pathway is Involved in the Effect of DHI on RSC96 Cells

Previous studies have shown that PI3K/Akt pathway is closely related to the proliferation and migration of cells. To verify whether PI3K/Akt pathway plays a role in the proliferation and migration of RSC96 cells induced by DHI, we detected the key signal proteins, including PI3K and AKT. We found that the expression of p-PI3K and p-AKT increased significantly after treatment with DHI, while the expression of PI3K, AKT, and GAPDH remained unchanged (Fig. 2). From this experiment, it was suggested that the PI3K/AKT pathway is involved in the effect of DHI on RSC96 cells.

DHI Increases the Expression of CXCL12 and GDNF in RSC96 Cells

CXCL12 is a common chemokine and is closely related to the migration of Schwann cells in our previous study, whereas GDNF is a neurotrophic factor closely associated with nerve injury and repair. To detect the effect of DHI on the secretion of these two factors in RSC96 cells, Western blot, RT-PCR, and ELISA experiments were used to detect the expression of CXCL12 and GDNF in RSC96 cells. As shown in Fig. 3A, after DHI treatment for 24 h, the expression of CXCL12 and GDNF protein was promoted by DHI in a concentration-dependent manner. RT-PCR experiments (Fig. 3C, D) showed that DHI increased the mRNA expression of CXCL12 and GDNF in RSC96 cells, and ELISA experiments (Fig. 3E, F) showed that the secretion of CXCL12 and GDNF increased in RSC96 cells.

The Enhanced Expression of CXCL12 in RSC96 Cells Induced by DHI Depends on PI3K/AKT Pathway

Western Blot, RT-PCR, and ELISA experiments were used to investigate the relationship between CXCL12 and GDNF expressed by RSC96 cells and the PI3K/AKT pathway. According to Fig. 4A, DHI-promoted CXCL12 expression was inhibited by LY294002, a PI3K protein inhibitor, while GDNF expression was not affected. Besides, the mRNA and secretory expression of CXCL12 also decreased after LY294002, while the mRNA and secretory expression of GDNF did not change significantly (Fig. 4C, D). In a word, these results indicated that DHI induced CXCL12 expression in RSC96 cells through the PI3K/AKT pathway.

DHI Promotes the Proliferation and Migration of RSC96 Cells Through PI3K/AKT Pathway

Previous studies have found that DHI promotes the expression of PI3K/AKT and CXCL12 in RSC96 cells. To determine whether the changes of PI3K/AKT/CXCL12 induced by DHI are related to the proliferation and migration of RSC96 cells, CCK-8 and Transwell experiments were conducted with LY294002 and CXCL12 antibodies combined with DHI, respectively. The results showed that the migration of RSC96 cells was not significantly affected by LY294002 and CXCL12 antibody alone, but was significantly increased after using DHI. This increased effect was weakened after the application of LY294002 and CXCL12 antibodies, however, it was still higher than that of the control group (Fig. 5A). Similar results were also found in the CCK8 assay of RSC96 cell viability (Fig. 5C). The increased cell proliferation viability caused by DHI was weakened after the addition of LY294002 and CXCL12 antibodies, while the application of LY294002 and CXCL12 antibodies alone had no significant effect on cell proliferation. These results...
DHI improves the neurological function scores of facial nerve-injured rats

To verify the effect of DHI on the repair of facial nerve injury in vivo, different concentrations of DHI were injected into rats after facial nerve injury, and facial nerve function scores were performed on the 1st, 7th, 14th, and 28th days. Our results showed that the sham-operated rats were always normal and the scores were always 10 points. According to Fig. 6A, facial nerve scores improved to varying degrees in all groups except the sham-operated group. There was no statistical difference among these groups on the 7th day (Fig. 6B), however, the scores gradually increased and showed statistical significance on the 14th day, and the scores were further increased on the 28th day (Fig. 6C, D). Facial nerve scores increased with increasing doses of DHI, although no statistical difference was shown at high, medium, and low doses. This indicated that DHI can improve the functional recovery of the facial nerve in a dose-depending manner. To observe a more significant therapeutic effect of DHI, we used the data of high-concentration DHI in the presentation of the subsequent results.

DHI increases the expression of CXCL12 and GDNF in facial nerve-injured rats

Cell experiments have confirmed that DHI promotes the production of CXCL12 and GDNF in RSC96 cells. To further verify this result in vivo, the ELISA assay was used for detecting the expression of CXCL12 and GDNF on the 1st, 7th, 14th, and 28th days after facial nerve injury. The results (Fig. 7A, B) showed that the expression of CXCL12 and GDNF in the sham operation group was maintained at a stable level. The expression of CXCL12 in the FNI group increased after the operation, peaked at about 2 weeks, and then returned to the initial level at about 4 weeks. GDNF continued to increase at 1 day after the operation and remained at a high level at 4 weeks, however, the increased level slowed down later. In the H + DHI group, the expression levels of CXCL12 and GDNF continued to increase during DHI treatment, and the expression levels were significantly higher than those in the FNI group. This indicated that DHI can also promote the production of CXCL12 and GDNF in facial nerve tissue in vivo.

DHI promotes MBP and GAP-43 expression and restoration of facial nerve myelin structure

To detect the state of Schwann cells and nerve fibers after facial nerve injury, the immunofluorescence staining test
was used to stain the nerve tissue 28 days after the operation. According to the results (Fig. 8A–C), we found that the expression of MBP and GAP-43 was uniform around the nerves in the sham group, while the expression of MBP and GAP-43 in the FNI group was significantly decreased and the structure was disorganized. Compared with the FNI group, the expression of MBP and GAP-43 in the DHI group was significantly up-regulated, and the expression was more uniform around the nerve fibers. In addition, transmission electron microscopy of nerve thin sections showed that the morphology of myelin sheaths after DHI treatment was more regular and closer to the arrangement of the sham group compared to the FNI group (Fig. 8D). These results suggested that DHI promoted the re-enfolding of Schwann cells after facial nerve injury and functional recovery.

Discussion

The facial nerve, the seventh pair of cranial nerves in humans, originates intracranially and branches innervating the region of the head and neck and is a vulnerable nerve in otolaryngology. Facial nerve injury is often caused secondary to the congenital, infectious, idiopathic, iatrogenic, traumatic, neurological, tumor, or systemic etiology. The incidence of facial nerve injury is approximately 20–30 persons/ per year/ per 100,000 population [21]. Loss of facial nerve structural continuity caused by nerve injury not only causes salivation, eating difficulties, eye closure incompletely, but also causes corneal turbidity, blindness, and even facial muscle atrophy and linkage, resulting in expression stagnation and facial appearance damage, seriously affecting the patient’s quality of life and social activities. At present, the clinical treatment of facial nerve injury is not standardized, and further research is needed to improve the treatment effect. Clinical common medications include steroid hormones to relieve acute facial swelling [22], neurotrophic factors to stimulate the regeneration of neurons [23, 24], and incobotulinumtoxin A to relax stiff muscles [25]. In addition, another common approach is the surgical intervention of the facial nerve through nerve repair, replacement, and transplantation [26]. However, in general, patients with better outcomes also tend to have facial asymmetry and functional impairment. In this study, we focused on the Schwann
cells in the process of repairing facial nerve injury and the therapeutic effect of DHI on facial nerve injury. Our experiments proved that DHI could promote the proliferation and migration of RSC96 cells through the PI3K/Akt pathway, increase the expression of CXCL12 and GDNF, and promote the recovery of facial nerve function in rats (Fig. 9).

At the beginning of the study, different concentrations of DHI were used to study the effect of DHI on the proliferation and migration of RSC96 cells, and the appropriate DHI concentration for subsequent trials was selected to be 1%.

PI3K/AKT pathway is a common signaling pathway associated with cell proliferation and migration [27]. We studied its changes when DHI acts on RSC96 cells and found that PI3K/AKT is significantly activated, which was consistent with Zhou’s findings in atherosclerosis [28] and Feng’s study on cerebral ischemia/reperfusion injury [29] in which DHI activates the PI3K/AKT pathway.

GDNF is recognized as a nerve growth factor that promotes the growth of neurons [23], in addition to our previous studies we also found that a factor called CXCL12...
can promote the migration of Schwann cells [19]. To study the effect of DHI on the secretion of these two cytokines in RSC96 cells, we detected the effect of DHI on the expression of CXCL12 and GDNF. The results showed that DHI could promote the expression of these two factors at both animal and cell levels. To further study the relationship between the PI3K/Akt pathway and the secretion of CXCL12 and GDNF, cell proliferation and migration, the inhibitors of PI3K, LY294002, and CXCL12 antibodies were used for experiments. The results showed that CXCL12 expression significantly decreased after PI3K/AKT pathway was inhibited, while GDNF expression was not affected. Moreover, cell proliferation and migration were significantly reduced after the PI3K/AKT pathway was inhibited. The proliferation and migration of RSC96 cells induced by DHI at the cellular level have been determined, and we further performed

**Fig. 6** The dynamic changes of facial nerve function scores in different groups of rats after FNI. A Facial nerve scores of all groups at different time points. B The facial nerve scores of the FNI group and DHI groups on the 7th day. C The facial nerve scores of the FNI group and DHI groups on the 14th day. D The facial nerve scores of the FNI group and DHI groups on the 28th day. *p < 0.05, **p < 0.01 compared to the FNI group

**Fig. 7** DHI increases the expression of CXCL12 and GDNF in FNI rats. A DHI increases the expression of CXCL12 in facial nerve-injured rats. B DHI increases the expression of GDNF in facial nerve-injured rats. **p < 0.01, ***p < 0.001, ****p < 0.0001 compared to the control group.
immunofluorescence staining in animals to observe the expression of Schwann cells using molecular marker MBP caused by DHI. We found that DHI significantly promoted the MBP expression around the damaged facial nerve, that is, Schwann cells significantly increased after DHI treatment. Besides, facial nerve scores also demonstrated that the facial nerve function of rats after DHI treatment was significantly improved.

DHI is a widely used Chinese medicine in cardiovascular and cerebrovascular diseases. It has anti-inflammatory, scavenging free radicals, and circulatory promoting effects [15]. Numerous studies have found DHI has protective effects on...
the central nervous system, such as in ischemia-reperfusion injury model rats DHI can pass to protect the blood-brain barrier and reversal neutrophils infiltrating to play a protective role. For example, DHI protects the blood-brain barrier and reverses neutrophil infiltration in rat models of cerebral ischemia-reperfusion injury [30], and DHI increases the expression of astrocytes Peroxiredoxin 1 in subarachnoid hemorrhage models and reduces the expression of inflammatory factors such as tumor necrosis factor (TNF) and interleukin-1 (IL-1), thereby reducing hematoma volume and brain water content and improving neurological deficits [16].

Our study demonstrated for the first time the therapeutic effect of DHI on facial nerve injury, which provided an experimental basis for the clinical use of DHI in the treatment of facial nerve injury. Few studies have investigated the application of DHI in peripheral nerve injury. In addition to our study, another study found that DHI can alleviate mechanical abnormal pain in diabetic neuropathy rats by inhibiting the activation of ERK1/2, and DHI can increase the BDNF content in the sciatic nerve [31]. In conclusion, our experiments showed that DHI could promote cell proliferation and migration through the PI3K/AKT pathway and increase the expression of CXCL12 and GDNF, ultimately promoting the functional recovery of the facial nerve.

**Conclusions**

In conclusion, our in vitro and in vivo experiments demonstrated that DHI promotes the proliferation and migration of Schwann cells through the PI3K/AKT pathway, and increases the expression of CXCL12 and GDNF to promote facial nerve function repair.

**Acknowledgements** Thanks to the support of the National Natural Science Foundation of China (No. 82071069) and the technical platform provided by the Institute of otology.

**Author Contributions** DG and JH conceived the idea and wrote the manuscript. DG and LS performed the facial nerve injury model, drug administration, Western blot analysis, and immunofluorescence staining experiments. XS performed ELISA and RT-qPCR experiments. JY and JH reviewed and edited the final manuscript.

**Funding** We thank the support from the National Natural Science Foundation of China (No. 82071069).

**Data Availability** The data presented in this study are available on request from the corresponding author.

**Declarations**

**Conflict of interest** The authors declare that they have no conflict of interests.

**Informed Consent** Informed consent was obtained from all subjects involved in the study.

**References**

1. Vogelnik K, Matos A (2017) Facial nerve palsy secondary to Epstein-Barr virus infection of the middle ear in pediatric population may be more common than we think. Wien Klin Wochenschr 129:844–847
2. Hernandez-Trejo AF, Cuellar-Calderon KP, Treviño-Gonzalez JL, Yamamoto-Ramos M, Campos-Coy MA, Quiroga-Garza A, Guzman-Avilan K, Elizondo-Riosjas G, Elizondo-Omaña RE, Guzman-Lopez S (2020) Prevalence of facial canal dehiscence and other bone defects by computed tomography. Eur Arch Otorhinolaryngol 277(10):2681–2686
3. Ishii LE, Nellis JC, Boahene KD, Byrne P, Ishii M (2018) The importance and psychology of facial expression. Otalaryngol Clin N Am 51:1011–1017
4. Jessen KR, Misky R (2016) The repair Schwann cell and its function in regenerating nerves. J Physiol 594:3521–3531
5. Wood MD, Mackinnon SE (2015) Pathways regulating modality-specific axonal regeneration in peripheral nerve. Exp Neurol 265:171–175
6. Boyd JG, Gordon T (2003) Neurotrophic factors and their receptors in axonal regeneration and functional recovery after peripheral nerve injury. Mol Neurobiol 27:277–324
7. Rotshenker S (2011) Wallerian degeneration: the innate-immune response to traumatic nerve injury. J Neuroinflammam 8:109
8. Cattin AL, Burden JJ, Van Emmenis L, Mackenzie FE, Hoving CH, Querida V, Jamecna D, Napoli I, Parrinello S, Enver T, Ruhrberg C, Lloyd AC (2015) Macrophage-Induced blood vessels guide Schwann cell-mediated regeneration of peripheral nerves. Cell 162:1127–1139
9. Jessen KR, Misky R (2019) The success and failure of the Schwann cell response to nerve injury. Front Cell Neurosci 13:33
10. Gomez-Sanchez JA, Carty L, Iruarrizaga-Lejarreta M, Palomo-Iriegoyen M, Varela-Carmona M, Azkargorta A, Aurreroechea I, De Juan VG, Jefferies HB, Aspichuela F, Ertorta F, Aransay AM, Martinez-Chantar ML, Baas F, Mato JM, Misky R, Woodhoo A, Jessen KR (2015) Schwann cell autophagy, myelophagy, initiates myelin clearance from injured nerves. J Cell Biol 210:153–168
11. Li IP, Liu Y, Guo JM, Shang EX, Zhu ZH, Zhu KY, Tang YP, Zhao BC, Tang ZS, Duan JA (2017) A comprehensive strategy to evaluate compatibility of Chinese medicine injection and infusion solutions based on chemical analysis and bioactivity assay. Front Pharmacol 8:833
12. Hu Z, Wang H, Fan G, Zhang H, Wang X, Mao J, Zhao Y, An Y, Huang Y, Li C, Chang L, Chu X, LiLi, Li Y, Zhang Y, Qin G, Gao X, Zhang B (2019) Danhong injection mobilizes endothelial progenitor cells to repair vascular endothelium injury via upregulating the expression of Akt, eNOS and MMP-9. Phytomedicine 61:152850
13. Li ZM, Wu SW, Liu PQ (2018) Salvia miltiorrhiza Burge (Danshen): a golden herbal medicine in cardiovascular therapeutic. Acta Pharmacol Sin 39:802–824
14. Xu W, Zhang Y, Yu Y, Li B, Liu J, Wang P, Wu H, Liu Q, Wei Z, Xiao H, Wang Z (2018) Dose-dependent target diversion of Danhong injection on the Glu-GLT-1/Gly-GlyRα dynamic balance module of cerebral ischemia. Pharmacol Res 135:80–88
15. Feng X, Li Y, Wang Y, Li L, Little PJ, Xu SW, Liu S (2019) Danhong injection in cardiovascular and cerebrovascular diseases: pharmacological actions, molecular mechanisms, and therapeutic potential. Pharmacol Res 139:62–75
16. Wang S, Yu L, Sun G, Liu Y, Hu W, Liu Y, Peng T, Wang X, Cheng J, Qin B, Lu H (2020) Danhong injection protects hemorrhagic brain injury by increasing peroxiredoxin 1 in aged rats. Front Pharmacol 11:346
17. Deng W, Yang C, Xiong M, Fu X, Lai H, Huang W (2014) Danhong enhances recovery from residual dizziness after successful repositioning treatment in patients with benign paroxysmal positional vertigo. Am J Otolaryngol 35:753–757
18. Chen W, Yao X, Zhou C, Zhang Z, Gui G, Lin B (2017) Danhong huayu koufuye prevents diabetic retinopathy in streptozotocin-induced diabetic rats via antioxidation and anti-inflammation. Mediat Inflamm 2017:3059763
19. Gao D, Tang T, Zhu J, Tang Y, Sun H, Li S (2019) CXCL12 has therapeutic value in facial nerve injury and promotes Schwann cells autophagy and migration via PI3K-AKT-mTOR signal pathway. Int J Biol Macromol 124:460–468
20. de Faria SD, Testa JR, Borin A, Toledo RN (2006) Standardization of techniques used in facial nerve section and facial movement evaluation in rats. Braz J Otorhinolaryngol 72:341–347
21. Ali SA, Stubbins AW, Hanks JE, Kupfer RA, Hogikyan ND, Feldman EL, Brenner MJ (2020) Facial nerve surgery in the rat model to study axonal inhibition and regeneration. J Vis Exp 159:e59224
22. Lee PH, Liang CC, Huang SF, Liao HT (2018) The outcome analysis of traumatic facial nerve palsy treated with systemic steroid therapy. J Craniofac Surg 29:1842–1847
23. Ma F, Xu F, Li R, Zheng Y, Wang F, Wei N, Zhong J, Tang Q, Zhu T, Wang Z, Zhu J (2018) Sustained delivery of glial cell-derived neurotrophic factors in collagen conduits for facial nerve regeneration. Acta Biomater 69:146–155
24. Bendella H, Rink S, Grosheva M, Sarikcioglu L, Gordon T, Angelov DN (2018) Putative roles of soluble trophic factors in facial nerve regeneration, target reinnervation, and recovery of vibrissal whisking. Exp Neurol 300:100–110
25. Akulov MA, Orlova OR, Orlova AS, Usachev DJ, Shimansky VN, Tanjashin SV, Khokhlova SE, Yunosha-Shanyavskaya AV (2017) IncobotulinumtoxinA treatment of facial nerve palsy after neurosurgery. J Neurol Sci 381:130–134
26. Ozsoy U, Hirzay A, Demirel BM, Ozsoy O, Bilmen Sarikciloglu S, Turhan M, Sarikcioglu L (2011) The hypoglossal-facial nerve repair as a method to improve recovery of motor function after facial nerve injury. J Anat 193:304–313
27. Zhang L, Zhou F, ten Dijke P (2013) Signaling interplay between transforming growth factor-β receptor and PI3K/AKT pathways in cancer. Trends Biochem Sci 38:612–620
28. Zhou M, Ren P, Li S, Kang Q, Zhang Y, Liu W, Shang J, Gong Y, Liu H (2019) Danhong injection attenuates high-fat-induced atherosclerosis and macrophage lipid accumulation by regulating the PI3K/AKT insulin pathway. J Cardiovasc Pharmacol 74:152–161
29. Feng C, Wan H, Zhang Y, Yu L, Shao C, He Y, Wan H, Jin W (2020) Neuroprotective effect of danhong injection on cerebral ischemia-reperfusion injury in rats by activation of the PI3K-Akt pathway. Front Pharmacol 11:298
30. Wang S, Guo H, Wang X, Chai L, Hu L, Zhao T, Zhao B, Tan X, Jia F (2014) Pretreatment with Danhong injection protects the brain against ischemia-reperfusion injury. Neural Regen Res 9:1453–1459
31. Wang Q, Guo ZL, Aori GL, Kong DW, Yang WQ, Zhang L, Yu YB (2018) Danhong injection alleviates mechanical allodynia via inhibiting ERK1/2 activation and elevates BDNF level in sciatic nerve in diabetic rat. Evid Based Complement Altern Med 2018:5798453

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.